Volume 15, Number 6—June 2009
Dispatch
Leishmaniasis, Autoimmune Rheumatic Disease, and Anti–Tumor Necrosis Factor Therapy, Europe
Table
Patient no. | Country | Age, y/sex | Disease | Anti-TNF treatment | Other immunosuppressive treatments | Form of Leishmania infection | Ref. | |||
---|---|---|---|---|---|---|---|---|---|---|
Agent | Duration, mo | Agent(s) | Duration, mo | |||||||
1 | France | 66/M | ANCA-associated vasculitis | NA | NA | Cyclophosphamide, methotrexate, corticosteroids | 120 | Visceral | (7) | |
2 | Israel | 56/M | Rheumatoid arthritis | NA | NA | Methotrexate, corticosteroids | 120 | Cutaneous | (8) | |
3 | Italy | 35/M | Behçet disease | NA | NA | Chlorambucil, corticosteroids | 36 | Visceral | (9) | |
4 | Spain | 50/M | Rheumatoid arthritis | NA | NA | Methotrexate, corticosteroids | 120 | Visceral | (10) | |
5 | Italy | 60/M | Polyarteritis nodosa | NA | NA | Cyclophosphamide, corticosteroids | 2 | Visceral | (11) | |
6 | Spain | 55/M | Psoriatic arthritis | Infliximab | 9 | No details given | 300 | Visceral | (2) | |
7 | Italy | 76/M | ANCA-associated vasculitis | NA | NA | Cyclophosphamide, corticosteroids | 36 | Visceral | (12) | |
8 | France | 53/F | Rheumatoid arthritis | Infliximab | 12 | Azathioprine, corticosteroids | 12 | Visceral | (3) | |
9 | Italy | 69/F | Rheumatoid arthritis | Adalimumab | 25 | Methotrexate, corticosteroids | 360 | Visceral | (4) | |
10 | Greece | 60/F | Rheumatoid arthritis | Etanercept | 18† | Cyclosporine, corticosteroids, anakinra | 96 | Visceral | (5) | |
11 | France | 9/F | Juvenile rheumatoid arthritis | NA | NA | Cyclosporine, methotrexate, corticosteroids, anakinra | 60 | Visceral | (13) | |
12 | Greece | 45/M | Psoriatic arthritis | Infliximab | 60 | Methotrexate, corticosteroids | 60 | Visceral | (6) | |
13 | Greece | 65/F | Rheumatoid arthritis | NA | NA | Methotrexate | 96 | Visceral | (14) | |
14 | Greece | 71/F | Giant cell arteritis | Infliximab | 24 | Methotrexate, corticosteroids | 24 | Visceral | This study | |
15 | Greece | 55/M | Ankylosing spondylitis | Infliximab | 12 | Methotrexate | 12 | Cutaneous | This study |
*TNF, tumor necrosis factor; Ref., reference; ANCA, anti-neutrophil cytoplasmic antibody; NA, not applicable.
†All biologic treatments had been terminated 6 mo before leishmaniasis occurred.
References
- Winthrop KL. Risk and prevention of tuberculosis and other serious opportunistic infections associated with tumor necrosis factor. Nat Clin Pract Rheumatol. 2006;2:602–10. DOIPubMedGoogle Scholar
- Romani-Costa V, Sanchez C, Moya F, Estany C. Visceral leishmaniasis related to infliximab administration. Enferm Infecc Microbiol Clin. 2004;22:310. DOIPubMedGoogle Scholar
- Fabre S, Gibert C, Lechiche C, Dereure J, Jorgesen C, Sany J. Visceral leishmaniasis infection in a rheumatoid arthritis patient treated with infliximab. Clin Exp Rheumatol. 2005;23:891–2.PubMedGoogle Scholar
- Bassetti M, Pizzorni C, Gradoni L, Del Bono V, Cutolo M, Viscoli C. Visceral leishmaniasis infection in a rheumatoid arthritis patient treated with adalimumab. Rheumatology. 2006;45:1446–8. DOIPubMedGoogle Scholar
- Bagalas V, Kioumis I, Argyropoulou P, Patakas D. Visceral leishmaniasis infection in a patient with rheumatoid arthritis treated with etanercept. Clin Rheumatol. 2007;26:1344–5. DOIPubMedGoogle Scholar
- Tektonidou MG, Skopouli FN. Visceral leishmaniasis in a patient with psoriatic arthritis treated with infliximab: reactivation of a latent infection? Clin Rheumatol. 2008;27:541–2. DOIPubMedGoogle Scholar
- Zanaldi H, Rosenthal E, Marty P, Chichmanian RM, Pesce A, Cassuto JP. Visceral leishmaniasis associated with Wegener disease. Use of lipid complex amphotericin B and liposomal amphotericin B. Presse Med. 1999;28:959–61.PubMedGoogle Scholar
- Vardy DA, Cohen A, Kachko L, Zvulunov A, Frankenburg S. Relapse of cutaneous leishmaniasis in a patient with an infected subcutaneous rheumatoid nodule. Br J Dermatol. 1999;141:914–7. DOIPubMedGoogle Scholar
- Sirianni MC, Barbone B, Monarca B, Nanni M, Lagana B, Aiuti F. A case of Behçet’s disease complicated by visceral leishmaniasis and myelodysplasia: clinical considerations. Haematologica. 2001;86:1004–5.PubMedGoogle Scholar
- Baixauli Rubio A, Rodriguez Gorriz E, Campos Fernandez J, Calvo Catala J, Garcia Vicente S. Enfermedad oportunista poco frecuente en enfermo tratamiento immunosupresor por arthritis reumatoide. . Anales de Medicina Interna (Madrid). 2003;20:276–7.
- Scatena P, Messina F, Gori S, Ruocco L, Vignali C, Menichetti F, Visceral leishmaniasis in a patient treated for polyarteritis nodosa. Clin Exp Rheumatol. 2003;21(S32):S121–3.PubMedGoogle Scholar
- Sollima S, Corbellino M, Piolini R, Calattini S, Imparato S. Visceral leishmaniasis in a patient with Wegener’s granulomatosis. Rheumatology. 2004;43:935–7. DOIPubMedGoogle Scholar
- Koné-Paut I, Retornaz K, Garnier JM, Bader-Meunier B. Visceral leishmaniasis in a patient with systemic juvenile arthritis treated by IL-1RA agonist (anakinra). Clin Exp Rheumatol. 2007;25:119.PubMedGoogle Scholar
- Venizelos I, Tatsiou Z, Papathomas TG, Orazi A. Visceral leishmaniasis in a rheumatoid arthritis patient treated with methotrexate. Int J Infect Dis. 2008; epub ahead of print.PubMedGoogle Scholar
- Cush JJ. Biological drug use: US perspectives on indications and monitoring. Ann Rheum Dis. 2005;64:iv18–23. DOIPubMedGoogle Scholar
Page created: December 08, 2010
Page updated: December 08, 2010
Page reviewed: December 08, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.